Our antibodies are used worldwide

We are the original manufacturer and provider of over 22,000 validated primary antibodies extensively covering the human proteome

Our Anti-DSCC1 polyclonal used in lung cancer research

DSCC1 is a novel therapeutic target to treat lung adenocarcinoma. 

University School of Medicine, Hangzhou, 310006 China

Our anti-human GAPDH in brain cancer study

Understanding the role of CD97 in brain cancer.

Sept 2023 (Department of Neurosurgery, University of Miami Hospital, University of Miami, Coral Gables, USA).

Our anti-SPINK2 in acute myeloid leukemia research

SPINK2 as an adverse prognostic marker in acute myeloid leukemia (AML)

Multiplexed selectivity screening of anti-GPCR antibodies

June 2023 (Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, 171 65 Solna, Sweden)

GMFG expression in breast cancer tissues was analyzed using Polyclonal Anti-GMFB antibody

June 2023 (Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China)

Anti-PMCH polyclonal used in Amyotrophic Lateral Sclerosis research

May 2023 (Université de Strasbourg, INSERM, Mécanismes centraux et périphériques de la neurodégénérescence, UMR-S1118, Strasbourg, France)

Can we improve Metabolic Dysfunctions in Patients with Amyotrophic Lateral Sclerosis?

Anti-FLNB Triple A polyclonal antibody used for the IHC staining within pancreatic ductal adenocarcinoma tissue

May 2023 (Helmholtz Pioneer Campus, Helmholtz Zentrum München, Ingolstaedter Landstraße 1, 85764 Neuherberg, Germany)

Anti-IGFBP6 polyclonal in various cancer types researches

May 2023 (Tumor Etiology and Screening Department of Cancer Institute and General Surgery, The First Hospital of China Medical University, No. 155 North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, People’s Republic of China)

Usage of the Human Protein Atlas (HPA) database to examine INHA protein levels in lung carcinoma

April 2022 (Cheeloo College of Medicine, Qilu Hospital of Shandong University, Shandong University, 107 Wenhua Xi Road, Jinan 250012, China)

INHA: a novel potential diagnostic indicator for lung carcinoma (LUAD).

Our Anti-SOX6 in Parkinson's Disease Study

April 2023 (Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.).

Parkinson's disease is a neurodegenerative disorder that affects movement. It occurs due to low levels of dopamine in the area of the brain that facilitates movement (substantia nigra, pars compacta). Without sufficient dopamine, the brain is unable to transmit signals to correctly coordinate movement.

Featured in this study is our Anti-SOX6 (HPA001923) TripleA Polyclonal antibody used in multiplexed IHC-IF. 

Our anti-GFAP in Alzheimer’s disease study

March 2023 (The Chinese University of Hong Kong, Shatin, N.T., Hong Kong SAR, People’s Republic of China).

Patchouli alcohol: a promising natural treatment of Alzheimer’s disease?

Patchouli alcohol attenuates the cognitive deficits in a transgenic mouse model of Alzheimer’s disease. Featured in this study is our TripleA Polyclonal anti-GFAP (HPA056030). 

Our anti-TRPV2 in skin cancer research

March 2023 (INSERM, Rennes, France).

Our rabbit polyclonal anti-TRPV2 (HPA044993) was used to show that TRPV2 is essential for melanoma tumor cell migration and invasion.

Shoji KF et al. The mechanosensitive TRPV2 calcium channel promotes human melanoma invasiveness and metastatic potential. EMBO Rep. 2023 Feb 6:e55069.

Our anti-DMD in colorectal cancer research

February 2023 (National Yang-Ming Chiao Tung University, Taipei, Taiwan).

A novel combined therapeutic option for the treatment of colorectal cancer?

Chang YC, et al, Overexpression of synaptic vesicle protein Rab GTPase 3C promotes vesicular exocytosis and drug resistance in colorectal cancer cells. Mol Oncol. 2023 Jan 18.

Our anti-ZBTB18 helps to understand the mechanisms regulating metastasis

January 2023 (St. Jude Children’s Research Hospital, Memphis, USA).

Loss of ZBTB18 promotes metastasis: this study explores the role of the transcriptional repressor ZBTB18 in metastatic mechanisms.

Wang R, et al. ZBTB18 restricts chromatin accessibility and prevents transcriptional adaptations that drive metastasis. Sci Adv. 2023 Jan 6;9(1):eabq3951. 

Six of our polyclonals in kidney cancer research

January 2023 (the Clinical Proteomic Tumor Analysis Consortium, USA).

This study enhances our understanding of kidney cancer, a complex and heterogeneous disease, by utilizing various analytical approaches.

Li Y, et al. Clinical Proteomic Tumor Analysis Consortium.
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. Cancer Cell. 2023 Jan 9;41(1):139-163.e17.

Our anti-SFXN4 in ovarian cancer therapy

January 2023 (Department of Molecular Biology and Biophysics, University of Connecticut Health Center, Farmington, CT, 06030, USA)

Sideroflexin 4 is overexpressed in ovarian cancer tissue and ovarian cancer cell lines.

Tesfay, L., Paul, B.T., Hegde, P. et al. Complementary anti-cancer pathways triggered by inhibition of sideroflexin 4 in ovarian cancer. Sci Rep 12, 19936 (2022).


Our Polyclonal Anti-HOPX Antibody in embryonic lung development research

December 2022 (Cardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL), Justus-Liebig University Giessen, Giessen, Germany).

New findings help build a model for the specific role of FGFR2b signalling on distal epithelial progenitors during pseudo-glandular lung development.

Jones, M.R., Lingampally, A., Ahmadvand, N. et al. FGFR2b signalling restricts lineage-flexible alveolar progenitors during mouse lung development and converges in mature alveolar type 2 cells. Cell. Mol. Life Sci. 79, 609 (2022)

Our Anti-OTP for diagnostics and classification of lung cancer

December 2022 (Department of Pathology GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, The Netherlands)

Understanding bipolar disorder and schizophrenia using a panel of our antibodies

November 2022 (Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany)

Anti-RNF39 polyclonal antibody in salivary duct carcinoma research

November 2022 (Division of Cellular Signaling, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan)

TMED9 as a Biomarker for Epithelial Ovarian Cancer (EOC)

November 2022 (Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea)

TMED9 (transmembrane emp24 domain-containing protein 9), which regulates the innate immune system and the protein transport via the ER-Golgi cargo pathway, has been implicated in various cancer types.

Han GH et al., TMED9 Expression Level as a Biomarker of Epithelial Ovarian Cancer Progression and Prognosis. Cancer Genomics Proteomics. 2022 Nov-Dec;19(6):692-702. 

Anti-TBX19 monoclonal antibody in pituitary tumor research

October 2022 (Department of Neurosurgery, Yonsei University College of Medicine, Seoul, South Korea)

Four of our antibodies in glioma research

October 2022 (Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden)

Our top 10 best-seller Anti-HNF1B monoclonal antibody used to stain human cancer tissue

October 2022 (Department of Pathology and Laboratory Medicine, Vancouver General Hospital and University of British Columbia, Vancouver, British Columbia, Canada)

Napsin-A and AMACR are superior to HNF-1β in distinguishing between mesonephric carcinomas and clear cell carcinomas of the gynecologic tract.

Mesonephric carcinomas are rare malignant tumors of the female uterine cervix commonly mistaken for an ovarian clear cell carcinoma due to their overlapping morphologic features.

Our antibodies to understand Ketogenic diet’s effect on brain cells

September 2022 (Department of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany)

Neuroscience: Ketogenic diet uncovers differential metabolic plasticity of brain cells.

The ketogenic diet is a low-carbohydrate, high-fat regime in which ketone bodies are utilized instead of glucose as an energy source.

Anti-DHX9 and Anti-SCO1 antibodies in research on the impact of histone density on cancer biology

September 2022 (The FIRC Institute of Molecular Oncology (IFOM), Milan, Italy)

The histone landscape in humans is complex: while there is only one histone H4 protein, diverse variants exist for H2A, H2B, and H3.

Anti-ACOX2 TripleA Polyclonal antibody in lung cancer research

September 2022 (Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA)

Our anti-DLX5 Triple A polyclonal antibody in reproductive organs development research

August 2022 (University of Texas MD Anderson Cancer Center, Houston, United States)

The reproductive tract organs of mammals are derived from two pairs of epithelial tubes surrounded by mesenchyme called the Wolffian ducts (progenitor male reproductive tract) and Müllerian ducts (progenitor female reproductive tract).

Anti-TOMM20 polyclonal helps to reveal mitochondria's contribution to inflammatory responses

August 2022 (School of Kinesiology, Shanghai University of Sport, Shanghai, 200438, China)

Mitochondria's contribution to inflammatory responses.

Renal cell carcinoma research and anti-DSP polyclonal antibody

August 2022 (Department of Clinical Medicine, University of Bergen, 5021, Bergen, Norway)

Our anti-S100b monoclonal in wound healing research

August 2022 (Shanghai Jiao Tong University School of Medicine, China)

Schwann cells facilitate wound healing by releasing TGF-β3.

Squamous cell carcinomas and our anti-TMTC3 antibody

July 2022 (Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China)

Squamous cell carcinomas show a specific expression pattern of TMTC3. Moreover, high expressions of TMTC3 are associated with poor survival in esophageal squamous cell carcinomas patients.

Anti-MUC5B rabbit polyclonal in SARS-CoV-2 research

July 2022 (Department of Biomedical Sciences, University of North Dakota School of Medicine & Health Sciences, Grand Forks, North Dakota, USA)

SARS-CoV-2 preferentially infects goblet cells in the bronchial airway epithelium. Goblet cells are a specialized type of epithelial cell that secrete mucins (MUCs), significant mucus components.

Five of our antibodies in cortical neural stem cell research

July 2022 (Max Planck Institute for Molecular Genetics, Berlin, Germany)

The anti-TINAGL1 polyclonal antibody for breast cancer research

June 2022 (Nagoya City University Graduate School of Medical Sciences, Japan)

TINAGL1: a promising candidate biomarker and therapeutic target in breast cancer patients.

Our anti-CCL28 Triple A Polyclonal antibody in Lung disease research

June 2022 (Sanger Institute, Hinxton, CambridgeshireUnited Kingdom)

Urothelial carcinomas research and our anti-PYGB polyclonal antibody

May 2022 (Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea)

Our Anti-ANLN polyclonal antibodies in research on various types of cancer

May 2022 (Department of General Surgery, Fuyang Hospital Affiliated to Anhui Medical University, Fuyang, Anhui, China)

Using our Anti-ANLN polyclonal antibodies (HPA005680, HPA050556) this comprehensive analysis (Yanlong Shi, et al. 2022) reveals the carcinogenic and immunological roles of ANLN in human cancers. 

Six antibodies from Atlas Antibodies used in multiplexing

May 2022 (Technology Innovation Lab, New York Genome Center, USA)

"An open source toolkit for repurposing Illumina sequencing systems as versatile fluidics and imaging platforms".

Fluorescence microscopy is a crucial method in the life sciences. It requires automated execution to generate robust and reproducible data.

Accessibility to software, hardware, and protocol open platforms is therefore necessary to facilitate analysis and programmable applications without specialized engineering or software development expertise.

Anti-CDK16 TripleA Polyclonal antibody in breast cancer research

May 2022 (Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China)

Anti-SGPL1 antibody used in mitochondrial dysfunction research

April 2022 (German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany)

Mitochondrial energy production is finely tuned to interpret cellular needs accurately.

Our polyclonal anti-RNF113A antibody in neural stem cells research

April 2022 (Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, Greece)

RNF113A (Ring Finger Protein 113A) regulates survival and differentiation properties of neural stem cells.

Anti-SERPINA3 and anti-LGALS3BP antibodies in skin cancer research

April 2022 (Institute of Technology, University of Tartu, Nooruse 1, 50411 Tartu, Estonia)

Malignant melanoma is the most severe type of skin cancer with the highest mortality rate.

Our rabbit anti-human LRG1 antibody used in blood vascular endothelial cells research

April 2022 (Institute of Pharmaceutical Sciences, Zurich, Switzerland)

Anti-EMSY polyclonal antibody in lung cancer research

March 2022 (Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, USA)

Lung cancer: deregulation of the ubiquitin-proteasome system promotes suppression of innate immunity, which fosters lung cancer immune evasion.

Using anti-PCYT2 polyclonal antibody in muscle health and muscle aging research

March, 2022 (Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Austria)

Muscle degeneration (or muscle atrophy) is the wasting or thinning of muscle mass that leads to frailty and dependency in inherited diseases and aging, affecting hundreds of millions of people.

Anti-ARID1A polyclonal antibody in the study ”Relevance of ARID1A Mutations in Endometrial Carcinomas”

March, 2022 (Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy)

Using Atlas Antibodies rabbit anti-XK (HPA019036) polyclonal antibody for McLeod Syndrome and Chorea-Acanthocytosis diseases research

February, 2022 (Laboratory of Biochemistry and Immunology, Osaka University, Japan)

Three antibodies from Atlas Antibodies in Immuno Oncology - Hodgkin lymphoma research

February, 2022 (Department of Pathology and Medical Biology, University Medical Center Groningen, Netherlands)

Using anti-PPAT polyclonal antibody (HPA036091) in liver cancer research

January, 2022 (State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, China)

Anti-CYBRD1 (HPA014757) antibody for Glioma research - increased expression of CYBRD1

November, 2021 (Department of Clinical Medicine, College of Medicine, Hunan University of Chinese Medicine, China)

Four Atlas Antibodies TripleA Polyclonals used in the study about IDH mutation

November, 2021 (Key Laboratory of Ministry of Education for Medicinal Plant Resource and Natural Pharmaceutical Chemistry, China)

Anti-PKM and Anti-GSTP1 rabbit polyclonals used in „Novel Diagnostic Protein Biomarkers in Colorectal Cancer“

September, 2021 (Department of Clinical Medicine - Department of Haematology, Aarhus, Denmark)

Novel putative protein biomarkers for colorectal cancer (CRC) identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) with future  diagnostic potential.

Rabbit polyclonal anti-ADPRHL2/ARH3 used to gain insights into chromatin regulation and human disease

September, 2021 (University of Copenhagen, Denmark)

ADP-ribosylation is a reversible post-translational protein modification that regulates numerous processes, including DNA damage repair and chromatin remodeling.

Three antibodies anti-RBM3, anti-PDS5A and anti-PRR11 in pancreatic cancer research

August, 2021 (Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, Sweden)

Treatment options for patients with pancreatic cancer are limited, and chemotherapy remains the standard of care, leading to only modest survival benefits.

Anti-HRC antibody in study which defines HRC as a novel candidate oncogene involved in HCC metastasis

August, 2021 (Department of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)

Rabbit anti-human GOLGB1 polyclonal antibody in Centriole and Golgi microtubule nucleation research

July, 2021 (Molecular and Cellular Pharmacology Graduate Training Program, University of Wisconsin-Madison, USA)

Anti-human STK4 antibody in study to determine the most suitable therapy for the STK4-deficiency-related disease

June, 2021 (Department of Pediatric Immunology, Hacettepe University Medical School, Ankara, Turkey)

Polyclonal antibodies against APOH and MGAM in Behçet’s disease (BD) and Crohn’s disease (CD) research

June, 2021 (Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea)

Anti-Nanog (AMAb91393) monoclonal antibody in ovarian cancer study

May, 2021 (Division of Oncology, Department of Clinical Sciences Lund, Lund University and Skåne University Hospital, Sweden)

Anti-LRBA polyclonal antibody in a study ”Regulation of CTLA-4 recycling by LRBA and Rab11”

May, 2021 (Institute of Immunity and Transplantation, University College London, United Kingdom)

Cytotoxic T-lymphocyte-associated protein 4, also known as CTLA-4 or CD152 (cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses.

Study analyzes RAI2 protein expression in invasive breast cancer tissues by IHC using our anti-RAI2 polyclonal antibody


April, 2021 (Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan)

Anti-HMCES polyclonal antibody in study which suggests that HMCES is an attractive target for selective treatment of A3A-expressing lung adenocarcinoma


April, 2021 (Institute for Research in Biomedicine, Barcelona, Spain)

The capacity to repair damaged DNA may modulate individual susceptibility to develop lung cancer.

Antibody Anti-SCGB2A1 used to explore the human lacrimal gland using organoids and single-cell sequencing


April, 2021 (Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, University Medical Center Utrecht, Netherlands)

Treatment options for patients with lacrimal gland disorders are limited partly due to a lack of biological understanding.

Our two polyclonal antibodies used to identify alternate receptors for SARS-CoV-2 that might facilitate initial host cell infection

April, 2021 (Department of Biology, University of Waterloo, Ontario, Canada)

Anti-Golga3 antibody in the study ”Novel players and large-scale protein dynamics of BCR activation revealed by APEX2 proximity labelling of lipid rafts”


March, 2021 (Institute of Biomedicine and MediCity Research Laboratories, University of Turku, Finland)

“Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma” study used Anti-RRM2 polyclonal antibody

March, 2021 (Hopp Children’s Cancer Center Heidelberg, Germany)

Study reporting increased SLC16A1 mRNA expression level in high-grade gliomas used our anti-SLC16A1 polyclonal antibody


March, 2021 (Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan)

Anti-TBX5 antibody and single-cell transcriptomic analysis uncover a novel relationship between specified cardiac progenitor cells and SHF progenitors


February, 2021 (Division of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, USA)